Department of Medicine
University of Wisconsin
H IAN ROBINS
Contact Information
600 HIGHLAND AVE
MADISON, WI 53792
Mail Code: 5664
Biography
Dr. Robins is chairman of the Systemic Hypothermia Oncological working group, an international cooperative group which conducts clinical trials. His activities regarding neuro-oncology include the development of protocols for which he is the Principle investigator in the Radiation Therapy oncology group, the Eastern Cooperative Oncology group, and the North American Brain Tumor Consortium.Specialty: Oncology
Appointment phone: 608-263-8090
800 Appointment phone: 800-323-8942
Primary practice location: UW Hospital and Clinics - Medical Oncology, 600 Highland Ave., Madison, WI 53592
Primary hospital affiliation(s): UW Hospital and Clinics
Board certification(s): Internal Medicine, Medical Oncology
Multidisciplinary clinic(s): Cancer - Brain Tumor Clinic
Medical interests: Breast cancer, clinical hypnosis, lymphomas - low grade, malignant melanoma, neuro-oncology, sarcomas, systemic hyperthermia
Medical School: Boston University
Internship: UW Hospital and Clinics
Residency: UW Hospital and Clinics
Fellowship: UW Comprehensive Cancer Center
Search for H Ian Robins' literature abstracts on PubMed
Katschinski, D.M., Robins, H.I. Hyperthermic modulation of SN-38-induced cleavable complex formation and cytotoxicity through altered topoisomerase I activity. Int. J. of Cancer: 80: 104-109, 1999.
Robins, H.I., Katschinski, D.M., Longo, W., Grosen, E., Wilding, G., Gillis, W., Kraemer, C., Tiggelaar, C.L., Rushing, D., Stewart, J.A., Spriggs, D., Love, R., Arzoomanian, R.Z., Feieabend, C., Alberti, D., Morgan, K., Simon, K., d'Oleire, F. A Pilot Study of Melphalan, Tumor Necrosis Factor-a and 41.8°C Whole Body Hyperthermia. Cancer Chemotherapy and Pharmacology: (43) 409-414, 1999.
Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Spence, A.M., Berger, M.S., Mehta, M.P., Bozik, M.E., Pollack, I., Schiff, D., Gilbert, M., Rankin, C., Prados, M.D. A phase II Study of phenylacetate in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Report. J. Clin. Oncol. 17(3): 984-990, 1999.
Katschinski, D.M., Wiedemann, G.J., d'Oleire, F.R., Longo, W., Robins, H.I. Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine and Growth Factor Reviews: 10: 93-97, 1999.
Robins, H.I., Grosen, E.G., Katschinski, D.M., Longo, W., Tiggelaar, C.L., Kutz, M., Winawer, J., Graziano, F. Whole body hyperthermia induction of soluble tumor necrosis factor receptors: Implications for Rheumatoid Diseases. J. Rheumatology: 26:2513-2516, 1999.
Katschinski, D.M., Robins, H.I., Schad, M., Frede, S., Fandrey, J. Role of TNFa in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res: 59:3404-3410, 1999.
Robins, H.I., Tutsch, K., Katschinski, D.M., Mehta, M., Jacobson, E., Olsen, M., Cohen, J.D., Tiggelaar, C.L., Arzoomanian, R.Z., Alberti, D., Feierabend, C., Wilding, G. A Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. J. Clin. Oncol: 17:2922-2931, 1999.
Gerke, P., Wojciech, F., Robins, H.I., Wiedemann, G.J., Steinhoff, J. Nephrotoxicity of ifosfamide, carboplatin and etoposide (ICE) alone or combined with extracorporeal or radiant heat induced whole body hyperthermia. J. Cancer Res Clin Oncol, 126: 173-177, 2000.
Sanghavi, S. Skrupski, R., Badie, B., Robins, H.I., Tome, W., Mehta, M.P. Recurrent malignant glioma treated with Radiosurgery. J. Radiosurg 2:119-125, 2000.
Robins, H.I., Howard, S.P., Mehta, M.P., Validity of Datasets Questioned in gliadel study. Managed Care & Cancer, 2(4):10, 2000.
Schold, S.C., Jr., Kuhn, J.G., Chang, S.M., Bosik, M.E., Robins, H.I., Mehta, M.P., Spence, A.M., Fulton, D., Fink, K.L., Prados, M.D. A phase I trial of 1,3-bis(2-chloroethyl)- nitrosourea plus temozolomide: A North American Brain Tumor Consortium Study. Neuro-Oncology, P. 34, 2000.
Katschinski, D.M., Jacobson, E.L., Wiedeman, G.J., Robins, H.I., Modulation of VP-16 cytotoxicity by carboplatin and 41.8° C hyperthermia. Cancer Res & Clin Oncol., 2001, 127: 425-432.
Westerman, A.M., Grosen, E.A., Katschinski, D.M., Jager, D., Rietbroek, R., Schink, J.C., Tigglar, C.L., Jager, E., Vorde sive Vording P.Z., Neuman, A., Knuth, A., Van Dijk, J.D.P., Wiedeman G.J., Robins, H.I. A pilot Study of Whole Body Hyperthermia nad Carboplatin in Platinum Residant Ovarian. Eur J Cancer. 2001. 37:1111-1117.
Chang S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Jr, Spence, A.M., Berger, M.S., Mehta, M.P., Pollack, I., Rankin, C., Prados, M.D. A phase II study of paclitacel (Taxol) using different doses depending on the concomitant use of anticonvulsants, in patients with recurrent malignant glioma. A North American Brain Tumor Consortium Report. Cancer, 91:417-22, 2001.